Phase II study of avelumab in multiple relapsed/refractory germ cell cancer
Conclusions This study failed to achieve its primary endpoint. Our data suggest a lack of avelumab efficacy in unselected multiple relapsed/refractory GCTs.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Germ Cell Tumors | Investigational New Drugs | Study | Toxicology